Contraindicated. Coadministration not proposed; robust cytochrome P450 enzyme inducers minimize systemic publicity to roflumilast and could decrease the therapeutic effectivenessPrevent; coadministration with CYP3A inducers could lead to reduced plasma concentrations of elvitegravir and/or possibly a concomitantly administered protease inhibitor an